Isolated Hepatocyte Transplantation for Crigler-Najjar Syndrome Type 1

Crigler-Najjar syndrome type 1 (CN1) is an inherited disorder characterized by the absence of hepatic uridine diphosphoglucuronate glucuronosyltransferase (UDPGT), the enzyme responsible for the conjugation and excretion of bilirubin. We performed allogenic hepatocyte transplantation (AHT) in a child with CN1, aiming to improve bilirubin glucuronidation in this condition. A 9-year-old boy with CN1 was prepared with plasmapheresis and immunosuppression with prednisolone and tacrolimus. When a graft was made available, 7.5 × 109 hepatocytes were isolated and infused into the portal vein percutaneously. After 2 weeks phenobarbitone was added to promote the enzymatic activity of UDPGT of the transplanted hepatocytes. Nocturnal phototherapy was continued throughout the studied period. Total bilirubin was considered a reliable marker of allogenic cell function. There was no significant variation of vital signs nor complications during the infusion. Mean ± SD bilirubin level was 530 ± 38 μmol/L before and 359 ± 46 μmol/L after AHT (t-test, p < 0.001). However, the introduction of phenobarbitone was followed by a drop of tacrolimus level with increase of alanine aminotransferase (ALT) and increase of bilirubin. After standard treatment of cellular rejection bilirubin fell again but from then on it was maintained at a greater level. After discharge the patient experienced a further increase of bilirubin that returned to predischarge levels after readmission to the hospital. This was interpreted as poor compliance with phototherapy. Only partial correction of clinical jaundice and the poor tolerability to nocturnal phototherapy led the parents to refuse further hepatocyte infusions and request an orthotopic liver transplant. After 24 months the child is well, with good liver function on tacrolimus and prednisolone-based immunosuppression. Isolated AHT, though effective and safe, is not sufficient to correct CN1. Maintenance of adequate immunosuppression and family compliance are the main factors hampering the success of this procedure.

[1]  A. Moser,et al.  Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. , 2003, Transplantation.

[2]  S. Strom,et al.  Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. , 2003, Pediatrics.

[3]  G. Abatangelo,et al.  Hepatocyte Transplantation in the Treatment of Acute Liver Failure: Microencapsulated Hepatocytes versus Hepatocytes Attached to an Autologous Biomatrix , 2003, Cell transplantation.

[4]  A. Granato,et al.  Hepatocyte transplantation as a treatment for glycogen storage disease type IA , 2002 .

[5]  C. Dunbar,et al.  Retroviral transduction and engraftment ability of primate hematopoietic progenitor and stem cells transduced under serum-free versus serum-containing conditions. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  A. Granato,et al.  Hepatocyte transplantation as a treatment for glycogen storage disease type 1a , 2002, The Lancet.

[7]  B. Portmann,et al.  LATE CELLULAR REJECTION IN PAEDIATRIC LIVER TRANSPLANTATION: AETIOLOGY AND OUTCOME , 2002, Transplantation.

[8]  A. Criel,et al.  Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing , 2001, Bone Marrow Transplantation.

[9]  M. Rela,et al.  Auxiliary partial orthotopic liver transplantation for Crigler-Najjar syndrome type I. , 1999, Annals of surgery.

[10]  R. Steffen.  Treatment of the Crigler-Najjar Syndrome Type I with Hepatocyte Transplantation , 1999 .

[11]  S. Strom,et al.  Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. , 1998, The New England journal of medicine.

[12]  J. Seppen,et al.  Serum-free production, concentration and purification of recombinant retroviruses. , 1997, BioTechniques.

[13]  P. Rosenthal,et al.  Current therapy for Crigler‐Najjar syndrome type 1: Report of a world registry , 1996, Hepatology.

[14]  R. Witkamp,et al.  Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. , 1996, Toxicology and applied pharmacology.

[15]  M. Schilsky,et al.  Conditional immortalization of gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin‐UDP‐glucuronosyltransferase gene transfer , 1995, Hepatology.

[16]  P. Bosma,et al.  Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. , 1994, The Journal of clinical investigation.

[17]  J. Emond,et al.  Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1 , 1993, The Lancet.

[18]  J H Southard,et al.  Principles of solid-organ preservation by cold storage. , 1988, Transplantation.

[19]  B. Gridelli,et al.  Orthotopic liver transplantation for type I Crigler‐Najjar syndrome , 1986, Hepatology.

[20]  J. Crigler,et al.  Congenital familial nonhemolytic jaundice with kernicterus. , 1952, Pediatrics.

[21]  S. Bigner,et al.  Evaluation of an automated technique for assessment of marrow engraftment after allogeneic bone marrow transplantation using a commercially available kit. , 2000, American journal of clinical pathology.

[22]  D. Asher.  The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics. , 1999, Developments in biological standardization.

[23]  S. Pett,et al.  Crigler-Najjar syndrome types I and II. Clinical experience--King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation. , 1987, Molecular aspects of medicine.